OSSIO Set to Premiere New ACL Interference Screw at AOSSM Annual Meeting

OSSIO Inc. is using the American Orthopaedic Society for Sports Medicine (AOSSM) 2026 Annual Meeting to its advantage this week, unveiling a new product, releasing study data, and announcing an athletic competition sponsorship.

The company is planning the following announcements/activities during the four-day meeting in Seattle:

• Update on the KneeBar Procedure study. Interim results from the multicenter, 50-patient clinical study of the company’s KneeBar Procedure will be discussed by orthopedic surgeon/professor Brian Cole, M.D., of Rush University Medical Center on July 10 during a breakfast symposium that features a presentation by Mayo Clinic researcher/orthopedic surgeon Aaron Krych, M.D. The symposium will focus on the underlying pathology of subchondral insufficiency tibia and femur fractures, which can cause knee joint edema and pain.
• Launch of the OSSIOfiber interference screw. OSSIO is expanding its sports medicine portfolio by introducing the OSSIOfiber interference screw, a bio-integrative, metal-free fixation solution designed primarily for anterior cruciate ligament (ACL) reconstruction. Built with the company’s proprietary platform technology, the implant delivers metal-like fixation strength while ultimately integrating into the patient’s native bone. The result is a restored orthopedic landscape without permanent hardware or residual implant material, helping simplify revision ACL reconstruction or other future surgeries. The implant provides secure graft fixation with a material that is five times stronger than traditional bio-composites, two times stronger than PEEK and one-and-a-half times stronger than cortical bone.
• Sponsorship of MoonPay X Games New Orleans 2026. As an official partner of the X Games, OSSIO will showcase its portfolio of bio-integrative, metal-free orthopedic fixation solutions at the X Games League Championship event in New Orleans (July 24–26). Through an in-person direct-to-patient activation at the Caesars Superdome, OSSIO will bring the power of OSSIOfiber Intelligent Bone Regeneration Technology to thousands of attendees and elite athletes at the Games, plus the approximately 20 million social followers and global ESPN audience expected to follow the event’s live stream.
• Direct-to-patient campaign expansion. In parallel, OSSIO is expanding its national direct-to-patient campaign to include the KneeBar Procedure, broadening awareness of bio-integrative treatment options for patients struggling with persistent pain caused by insufficiency fractures in the bone around the knee. By scaling awareness across digital and social platforms, OSSIO is rewriting patient expectations from knee treatment and connecting them directly with the surgeons who use OSSIOfiber solutions. The campaign’s message is simple: Preserve the natural knee by supporting the bone and addressing the underlying cause of pain.

Coincidentally, the company reached a major milestone in July with the 100,000th use of an OSSIOfiber implant in clinical practice, seven years since the technology’s commercial introduction in 2019.

The OSSIOfiber portfolio includes compression screws and staples, interference screws, suture anchors, fixation nails and other devices cleared by the U.S. Food and Drug Administration (FDA) for use in patients as young as two years old for alignment and fixation of fractures, osteotomies, arthrodesis and bone grafts, as well as soft tissue fixation to bone.

OSSIO is an orthopedic medical technology platform company aiming to transform the surgical experience for patients, physicians, providers, and payers. Founded in 2014, the company is striving to provide the first credible replacement for metal implants in the multibillion-dollar global orthopedic fixation market with OSSIOfiber Intelligent Bone Regeneration Technology. OSSIO conducts product development in Caesarea, Israel, and commercial operations from Palmetto, Fla., and Woburn, Mass.